- Home
- EDRY vs CMMB Comparison
EDRY vs CMMB Comparison
Compare EDRY & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDRY
- CMMB
- Stock Information
- Founded
- EDRY 2018
- CMMB 2004
- Country
- EDRY Greece
- CMMB Israel
- Employees
- EDRY N/A
- CMMB N/A
- Industry
- EDRY Marine Transportation
- CMMB Biotechnology: Pharmaceutical Preparations
- Sector
- EDRY Consumer Discretionary
- CMMB Health Care
- Exchange
- EDRY Nasdaq
- CMMB Nasdaq
- Market Cap
- EDRY 27.3M
- CMMB 22.0M
- IPO Year
- EDRY N/A
- CMMB N/A
- Fundamental
- Price
- EDRY $10.26
- CMMB $0.94
- Analyst Decision
- EDRY
- CMMB Strong Buy
- Analyst Count
- EDRY 0
- CMMB 2
- Target Price
- EDRY N/A
- CMMB $8.50
- AVG Volume (30 Days)
- EDRY 1.3K
- CMMB 122.5K
- Earning Date
- EDRY 08-11-2025
- CMMB 08-14-2025
- Dividend Yield
- EDRY N/A
- CMMB N/A
- EPS Growth
- EDRY N/A
- CMMB N/A
- EPS
- EDRY N/A
- CMMB N/A
- Revenue
- EDRY $49,707,775.00
- CMMB N/A
- Revenue This Year
- EDRY N/A
- CMMB N/A
- Revenue Next Year
- EDRY $28.27
- CMMB N/A
- P/E Ratio
- EDRY N/A
- CMMB N/A
- Revenue Growth
- EDRY N/A
- CMMB N/A
- 52 Week Low
- EDRY $7.60
- CMMB $0.87
- 52 Week High
- EDRY $20.90
- CMMB $2.55
- Technical
- Relative Strength Index (RSI)
- EDRY 49.29
- CMMB 32.90
- Support Level
- EDRY $10.18
- CMMB $0.89
- Resistance Level
- EDRY $10.99
- CMMB $0.97
- Average True Range (ATR)
- EDRY 0.48
- CMMB 0.06
- MACD
- EDRY -0.07
- CMMB -0.00
- Stochastic Oscillator
- EDRY 17.45
- CMMB 25.76
About EDRY EuroDry Ltd.
EuroDry Ltd is a holding company. It is a provider of ocean-going transportation. The company owns and operates dry bulk carriers that transport bulk such as iron ore, coal, and grains, and minor bulks such as bauxite, phosphate, and fertilizers. It operates under one operating and one reportable segment, that of operating dry bulk vessels.
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.